nach oben

Current Urology Reports

Erschienen in:

01.02.2014 | Female Urology (K Kobashi, Section Editor)

Painful Bladder Syndrome: An Update and Review of Current Management Strategies

verfasst von: Anthony J. Dyer, Christian O. Twiss

Erschienen in: Current Urology Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Interstitial cystitis/painful bladder syndrome (IC/PBS) remains a prevalent, but untreated disease with a poorly understood pathophysiology. Nonetheless, four main processes currently appear to be involved in producing IC/PBS symptoms: (1) disruption of the bladder GAG/proteoglycan layer, (2) upregulated immune/inflammatory response, (3) neural upregulation, and (4) pelvic floor dysfunction. Current and emerging therapies aimed at these potential targets will be the focus of this review with an update on IC/PBS therapy.

Skene AJC. Diseases of the bladder and urethra in women. New York, NY: Wm Wood; 1887. p. 167.

Hunner GL. A rare type of bladder ulcer in women: report of cases. Boston Med Surg J. 1915;172:660–4.

Hand JR. Interstitial cystitis: report of 223 cases (204 women and 19 men). J Urology. 1949;61:291–309.

4.••

Hanno PM, Allen D, Burks JQ, Roger C, et al. AUA guidelines for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70. AUA Guidelines based upon a systematic review of the literature through July, 2009. The guideline panel identifies an overall management strategy for IC/PBS using clinical principles and expert opinion.PubMed

Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, MD, August 28–29, 1987. J Urology. 1988;140:203–6.

Fall M, Oberpenning F, Peeker R. Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? Eur Urology. 2008;54(1):65–75.

Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28:274.PubMed

Elliott CS, Payne CK. Interstitial cystitis and the overlap with overactive bladder. Curr Urol Rep. 2012;13(5):319–26.PubMed

Leppilahti M, Tammela TL, Heini H, et al. Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J Urology. 2002;168:139.

10.

Lifford KL, Curhan GC. Prevalence of painful bladder syndrome in older women. J Urol. 2008;73:494.

11.

Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urology. 2005;174:2231–4.

12.

Clemens JQ, Meenan RT, O’Keeffe, et al. Prevalence of interstitial cystitis symptoms in a managed care population. J Urology. 2005;174:576–80.

13.

Inoue Y, Mita K, Kakehashi M, Kato M, Usui T. Prevalence of painful bladder syndrome (PBS) symptoms in adult women in the general population in Japan. Neurourol Urodyn. 2009;28(3):214–8.PubMed

14.

Berry S, Bogart L, Phama C, Liua K, Nybergc L, Stotoa M, et al. Development, Validation and Testing of an Epidemiological Case Definition of Interstitial Cystitis/Painful Bladder Syndrome. J Urology. 2010;183:1848–52.

15.

Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, et al. ; European Association of Urology. EAU guidelines on chronic pelvic pain. Eur Urology. 2010;57(1):35–48.

16.

Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 2007;69:9–16.PubMed

17.

Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol. 1994;152:1641–5.PubMed

18.

Neuhaus J et al. Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (IC/PBS/IC). World J Urol. 2012;30:693–700.PubMed

19.

Ford AP, Gever JR, Nunn PA, et al. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol. 2006;147:S132–43.PubMed

20.

Murkerji G, Yiangou U, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urology. 2006;176:367–73.

21.

Meares EM. Interstitial cystitis 1987. Urology. 1987;29(Suppl):46–8.PubMed

22.

Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology. 2007;69(4 Suppl):24–33.PubMed

23.

Twiss C, Kilpatrick L, Craske M, Buffington CA, Ornitz E, Rodríguez LV, et al. Increased startle responses in interstitial cystitis: evidence for central hyperresponsiveness to visceral related threat. J Urol. 2009;181(5):2127–33.PubMed

24.

Cervigni M, Natale F, Nasta L, Padoa A, Voi R, Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:943–7.PubMed

25.

Shorter B, Lesser M, Moldwin R, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J Urology. 2007;178:145–52.

26.

Fisher BP, Bavendam TG, Roberts BW, et al. Blinded placebo controlled evaluation on the ingestion of acidic foods and their effect on urinary pH and the symptomatology of interstitial cystitis. FL, NIDDK: Orlando; 1993. p. 53.

27.

Friedlander JI, Shorter B, Moldwin RM. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/IC/PBS) and comorbid conditions. BJU Int. 2012;109(11):1584–91.PubMed

28.

Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis/bladder pain syndrome. Female Pelvic Med Reconstr Surg. 2011;17(1):36–9.PubMed

29.

Fitzgerald MP, Anderson RU, Potts J, et al. Randomized multi- center feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol. 2009;182:570–80.PubMedCentralPubMed

30.

Simons DG, Travell JG, Simons LS. Travell and Simons Myofascial Pain and Dysfunction: The Trigger Point Manual (2nd ed), vol. 1. Baltimore: Williams &Wilkins; 1999.

31.

Schmidt RA, Vapnek JM. Pelvic floor behavior and interstitial cystitis. Semin Urology. 1991;9:154.

32.

Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urology. 2001;166:2226–31.

33.••

Fitzgerald et al. Randomized multicenter feasibility trail of myofascial physical therapy for the treatment of urological chronic pelvic pain syndrome. J Urology. 2013;189:S75–85. Randomized clinical trial comparing global therapeutic massage to myofascial physical therapy. This study demonstrated a statistically significant beneficial effect of myofacial physical therapy in the treatment of IC/PBS.

34.

Ortho-McNeil Pharmaceutical I. Elmiron® 100 mg (pentosan polysulfate sodium) capsules [online]. Available from URL: http://www.orthoelmiron.com.

35.

Parsons CL. The therapeutic role of sulfated polysaccharides in the urinary bladder. Urol Clin North Am. 1994;21(1):93–100.PubMed

36.

Parsons CL, Forrest J, Nickel JC, et al. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 2002;59(3):329–33.PubMed

37.

Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urology. 2008;179(1):177–85.

38.

Mulholland SG, Hanno P, Parsons CL, et al. Pentosan polysulfate sodium for therapy of interstitial cystitis: a double-blind placebo-controlled clinical study. Urology. 1990;35(6):552–8.PubMed

39.

Parsons CL, Benson G, Childs SJ, et al. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urology. 1993;150(3):845–8.

40.

Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urology. 1987;138:503.

41.

Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, Kaufman D, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65(4):654–8.PubMed

42.

Glazener CMA, Evans JHC, Peto R. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database of Systematic Reviews 2003, Issue 3.

43.

Pranikoff K, Constantino G. The use of amitriptyline in patients with urinary frequency and pain. Urology. 1998;51(5A Suppl):179–81.PubMed

44.

Van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urology. 2004;172:533.

45.

Fenton BW. Limbic associated pelvic pain: a hypothesis to explain the diagnostic relationships and features of patients with chronic pelvic pain. Med Hypotheses. 2007;69(2):282–6.PubMed

46.

Foster Jr HE, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urology. 2010;183(5):1853–8.

47.

Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J Urology. 1989;141:846.

48.

Thilagarajah R, Witherow RO'N, Walker MM. Quantitative histopathology can aid diagnosis in painful bladder syndrome. J Clin Pathol. 1998;51:211–4.PubMed

49.

Kastrup J, Hald T, Larsen S, Nielsen VG. Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis. Br J Urology. 1983;55:495–500.

50.

Larsen S, Thompson SA, Hald T, et al. Mast cells in interstitial cystitis. Br J Urology. 1982;54:283–6.

51.

Dasgupta P, Sharma SD, Womack C, et al. Cimetidine in painful bladder syndrome: a histopathological study. BJU Int. 2001;88:183.PubMed

52.

Seshadri P, Emerson L, Morales A. Cimetidine in the treatment of interstitial cystitis. Urology. 1994;44:614.PubMed

53.

Theoharides TC. Hydroxyzine for interstitial cystitis. J Allergy Clin Immunol. 1993;91:686–7.PubMed

54.

Theoharides TC. Hydroxyzine in the treatment of interstitial cystitis. Urology Clin North Am. 1994;21:113–9.

55.

Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis: a survey of 374 patients. J Urology. 1993;149:465–9.

56.

Theoharides TC, Sant GR, El-Mansoury M, Letourneau RJ, Ucci Jr AA, Meares Jr EM. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J Urology. 1995;153:629–36.

57.

Sant GR. Intravesical 50 % dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis. Urology. 1987;29(Suppl):17–21.PubMed

58.

Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997;49:108.PubMed

59.

Letourneau R, Pang X, Sant GR, et al. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. Br J Urology. 1996;77:41.

60.

Moran PA, Dwyer PL, Carey MP, et al. Oral methotrexate in the management of refractory interstitial cystitis. Aust N Z J Obstet Gynaecol. 1999;39:468.PubMed

61.

Oravisto KJ and Alfthan OS: Treatment of interstitial cystitis with immunosuppression and chloroquine derivatives. Eur Urology 1976; 82.

62.

Van de Merwe J, Kamerling R, Arendsen E, Mulder D, Hooijkass HJ. Sjogren’s Syndrome in patients with interstitial cystitis. Acta Rhematol. 1993;20:962–6.

63.

Alagiri M, Chottiner S, Ratner V, et al. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology. 1997;49:52.PubMed

64.

Ogawa H, Kameda H, Amano K, et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19:162.PubMed

65.

Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urology. 2005;174:2235.

66.

Forrest JB, Payne CK, Erickson DR. Cyclosporin A for refractory interstitial cystitis/Bladder pain syndrome: experience of 3 tertiary centers. J Urology. 2012;188(4):1186–91.

67.

Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112:1472.PubMed

68.

Pisoni CN, Sanchez FJ, Karim Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol. 2005;32:1047.PubMed

69.

Kapitsinou PP, Boletis JN, Skopouli FN, et al. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford). 2004;43:377.

70.

Van de Merwe JP. Interstitial cystitis and systemic autoimmune disease. Nat Clin Pract Urology. 2007;4:484.

71.

Boye E, Morse M, Huttner I, Erlanger BF, McKinnon KJ, Klassen J. Immune complex-mediated interstitial cystitis as a major manifestation of systemic lupus erythematosus. Clin Immunol Immunopathol. 1979;13:67–76.PubMed

72.

Yang CC, Burks DA, Nyberg LM, et al. Early termination of a trial of mycophenolate mofetil for treatment of intersitital cystitis/painful bladder syndrome: lessons learned. J Urology. 2011;185(3):901–6.

73.

Delafoy L, Raymond F, Doherty AM, et al. Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. Pain. 2003;105:489.PubMed

74.

Jaggar SI, Scott HC, Rice AS. Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Br J Anaesth. 1999;83:442.PubMed

75.

Liu HT, Kuo HC. Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One. 2012;7(9):e44687.PubMedCentralPubMed

76.•

Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfied D. Proof of concept trail of Tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urology. 2011;185(5):1716–21. andomized, double-blind, placebo-controlled phase 2 clinical trial investigating tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor, as a treatment of IC/PBS. The study demonstrated a statistically significant decrease in daily pain score and improvement in global response assessment.

77.

Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. Br J Urology. 1994;73:504–7.

78.

Moldwin RM, Sant GR. Interstitial cystitis: a pathophysiology and treatment update. Clin Obstet Gynecol. 2002;45:259–72.PubMed

79.

Lose G, Frandsen B, Hojensgard JC, Jesperasan, Astrup T. Chronic interstitial cystitis. Increased levels of eosinophil cationic protein in serum and urine and an ameliorating effect of subcutaneous heparin. Scand J Urology Nephrol. 1983;17:159–61.

80.

Lose G, Jerpersen J, Frandsen B, Hojensgrad JC, Astrup T. Subcutaneous heparin in the treatment of interstitial cystitis. Scan J Urology Nephrol. 1985;19:27–9.

81.

Henry R, Patterson L, Avery N, et al. Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. J Urology. 2001;165:1900–3.

82.

Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65(1):45–8.PubMed

83.

Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.PubMed

84.

Nomiya A, Naruse T, Niimi A, Nishimatsu H, Kume H, Igawa Y et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urology. 2013.

85.

Jacob SW, Bischel M, Herschler RJ. Dimethyl sulfoxide (DSMO): A new concept in pharmacotherapy. Curr Ther Res. 1964;6:134–5.PubMed

86.

Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urology. 1988;140(1):36–9.

87.

Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis—a practical approach. Urology. 1997;49(5A Suppl):105–7.PubMed

88.

Biggers RD. Self-administration of dimethyl sulfoxide (DMSO) for interstitial cystitis. Urology. 1986;28:10–1.PubMed

89.•

Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–5. A prospective trial of patients receiving intravesical DMSO, hydrocortisone, heparin and bupivacaine for 12 weeks. This study demonstrated patient age, menopausal status, BMI, diabetes mellitus, and cystometric bladder capacity were associated with clinical response to this intravesical cocktail. Anesthetic bladder capacity <675 mL was the only independent predictor of treatment failure in this study.PubMed

90.

Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ES. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–9.PubMed

91.

Al Hadithi H, Tincello DG, Vince GS, Richmond DH. Leukocyte populations in interstitial cystitis and idiopathic reduced bladder storage. Urology. 2002;59:851–5.PubMed

92.

Tissot WD, Diokno AC, Peters KM. A referral center’s experience with transitional cell carcinoma misdiagnosed as interstitial cystitis. J Urology. 2004;172:478–80.

93.

Cole EE, Scarpero HM, Dmochowski RR. Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? Neurourol Urodyn. 2005;24:638.PubMed

94.

Erickson DR, Kunselman AR, Bentley CM, et al. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J Urology. 2007;177:556.

95.

Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology. 2005;66:494.PubMed

96.

Aihara K, Hirayama A, Tanaka N, Fujimoto K, Yoshida K, Hirao Y. Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: safety, diagnostic potential and therapeutic efficacy. Int J Urology. 2009;16(12):947–52.

97.

McCahy PJ, Styles RA. Prolonged bladder distension: experience in the treatment of detrusor overactivity and interstitial cystitis. Eur Urology. 1995;28:325.

98.

Glemain P, Riviere C, Lenormand L, et al. Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year. Eur Urology. 2002;41:79.

99.

Faraday M, Hubbard H, Kosiak B, et al. Staying at the Cutting Edge: a review and analysis of evidence reporting and grading: the recommendations of the American Urological Association. Br J Urology-Int. 2009;104:294.

100.

Hillelsohn JH, Rais-Bahrami S, Friedlander JI, Okhunov Z, Kashan M, Rose L, et al. Fulguration for Hunner Ulcers: Long-Term Clinical Outcomes. J Urology. 2012;188(6):2238–41.

101.

Rofeim O, Hom D, Freid RM, et al. Use of the neodymium: YAG laser for interstitial cystitis: a prospective study. J Urology. 2001;166:134.

102.

Cox M, Klutke JJ, Kutlke CG. Assess-ment of patient outcomes following sub-musocal injection if triamcinolone for treatment of Hunner’s ulcer subtype in-terstitial cystitis. Can J Urology. 2009;16:4536.

103.

Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342:665.PubMed

104.

Tirumur S, Al-Kurdi D, Latthe P. Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J. 2010;21:1285–300.

105.

Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute and chronic inflammation. BJU Int. 2008;101:366–70.PubMed

106.

Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU. 2009;104(5):657–61.

107.

Gottsh HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodynam. 2011;30:93–6.

108.•

Shie JH, Liu HT, Wang YS, Kuo HC. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU Int. 2013;111(4):638–46. his clinical trial demonstrated both histological and clinical evidence of positive response to repeated intravesical injections of BTX-A in IC/PBS patients.PubMed

109.

Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16(1):15–23.

110.

Nickel JC. Interstitial cystitis: Characterization and management of an enigmatic urologic syndrome. Rev Urology. 2002;4:112–21.

111.

Shaker H, Wang Y, Loung D, et al. Role of C-afferent fibres in the mechanism of action of sacral nerve root neuromodulation in chronic spinal cord injury. BJU Int. 2000;85:905–10.PubMed

112.

Elbadawi A. Interstitial cystitis: a critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis. Urology. 1997;49(suppl):14.PubMed

113.

Siegel S, Paszkiewicz E, Kirkpatrick C, et al. Sacral nerve stimulation in patients with chronic intractable pelvic pain. J Urology. 2001;166:1742–5.

114.

Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urology. 2003;169:1369–73.

115.

Zabihi N, Mourtzinos A, Maher MG, Raz S, Rodríguez LV. Short-term results of bilateral S2-S4 Sacral Neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:553–7.PubMed

116.

Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011;30(7):1271–5.PubMed

117.

Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int. 2011;107(8):1258–64.PubMed

118.

Gokyildiz S, Kizilkaya Beji N, Yalcin O, Istek A. Effects of percutaneous tibial nerve stimulation therapy on chronic pelvic pain. Gynecol Obstet Invest. 2012;73(2):99–105.PubMed

119.

O'Reilly BA, Dwyer PL, Hawthorne G, Cleaver S, Thomas E, Rosamilia A, et al. Transdermal posterior tibial nerve laser therapy is not effective in women with interstitial cystitis. J Urology. 2004;172(5 Pt 1):1880–3.

120.

Rössberger J, Fall M, Jonsson O, Peeker R. Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology. 2007;70:638–42.PubMed

121.

Reimer K, Fleischer W, Brogmann B, et al. Povidone-iodine liposomes—an overview. Dermatology. 1997;195(suppl):93.PubMed

122.

Tyagi P, Wu PC, Chancellor MB, et al. Recent advances in intravesical drug/gene delivery. Molec Pharmaceut. 2006;4:369.

123.

Fraser MO, Chuang YC, Tyagi P, et al. Intravesical liposomes administration: a novel treatment for hyperactive bladder in the rat. Urology. 2003;61:656.PubMed

124.

Chuang YC, Lee WC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urology. 2009;182(4):1393–400.

125.

Lee WC, Chuang YC, Lee WC, Chiang PH. Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci. 2011;27(10):437–40.PubMed

126.

Hader JE, Marzella L, Myers RA, Jacobs SC, Naslund MJ. Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urology. 1993;149(6):1617–21.

127.

Weiss JP, Mattei DM, Neville EC, Hanno PM. Primary treatment of radiation-induced hemorrhagic cystitis with hyperbaric oxygen: 10-year experience. J Urology. 1994;151(6):1514–7.

128.•

Tanaka T, Nitta Y, Morimoto K, Nishikawa N, Nishihara C, Tamada S, et al. Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan. BMC Urol. 2011;11:11. A case series of 11 patients with refractory IC/PBS. All patients had failed conventional therapy. Treatment led to decrease in pelvic pain and urgency scales in the majority of patients.PubMedCentralPubMed

129.

Gallego-Vilar D, García-Fadrique G, Povo-Martin I, Salvador-Marin M, Gallego-Gomez J. Maintenance of the response to dimethyl sulfoxide treatment using hyperbaric oxygen in interstitial cystitis/painful bladder syndrome: a prospective, randomized, comparative study. Urology Int. 2013;90(4):411–6.

Titel: Painful Bladder Syndrome: An Update and Review of Current Management Strategies
verfasst von: Anthony J. Dyer
Christian O. Twiss
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 2/2014
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-013-0384-z

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Painful Bladder Syndrome: An Update and Review of Current Management Strategies

Abstract

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Implications of the FDA Statement on Transvaginal Placement of Mesh: The Aftermath

Prevention and Treatment of Biopsy-Related Complications

Repair of Pelvic Organ Prolapse: What is the Goal?

Trends in Surgical Management of T1 Renal Cell Carcinoma

Affordable Care Act: Implications in Female Pelvic Medicine and Reconstructive Surgery

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie